Managing Rivaroxaban

Veröffentlicht von: HealthObs

Beschreibung

The Rivaroxaban App is designed for doctors to help them manage patients on the anticoagulant rivaroxaban. It will be useful to general practitioners, cardiologists, haematologists, neurologists, anaesthetists, emergency specialists and surgeons. In fact most clinicians will at some time have patients on anticoagulants and would find this App helpful.
The Rivaroxaban App will help you
• Provide dosing advice for your patient.
• Provide safe advice if bleeding occurs.
• Recommend when to stop treatment before surgery.
• Interpret coagulation results.
--------------------------------------------------------------------------
Features of the Rivaroxaban App
Dose recommendation
The Rivaroxaban App offers the correct dose for the correct indication in line with the published data sheet.
Drug information
Details of the common side-effects, potential drug interactions and basic pharmacology is immediately available.
Managing bleeding
Bleeding is a potential problem with any anticoagulant and can be complex to manage. The Rivaroxaban App provides advice about which treatments to use for both minor and major bleeding.
Managing surgery
A common question with any anticoagulant is how long should treatment be stopped before surgery? The Rivaroxaban App calculates a safe interval between stopping treatment and surgery and offers advice for treatment prior to emergency surgery if the surgery cannot be delayed.
Referenced information
All recommendations are linked to an information page which is appropriately referenced.
Website for feedback
The Rivaroxaban App is linked to the HealthObs website to allow you to ask questions, provide feedback or even start a discussion.
We welcome all feedback.
----------------------------------------------------------------
The advice is based on published reviews and guidelines. Extensive efforts have been made to ensure the accuracy of the information however information may change for specific countries at short notice. The user should refer to the manufacturers datasheet for complete prescribing information.
Disclaimer
This software is to be used as a guide only and healthcare professionals should use clinical judgement and should individualise care for each patient. In no event shall the author or developer be liable to any party for damages resulting from the use of this application.
Ausblenden Mehr anzeigen...

Screenshots

Managing Rivaroxaban Häufige Fragen

  • Ist Managing Rivaroxaban kostenlos?

    Ja, Managing Rivaroxaban ist komplett kostenlos und enthält keine In-App-Käufe oder Abonnements.

  • Ist Managing Rivaroxaban seriös?

    Nicht genügend Bewertungen, um eine zuverlässige Einschätzung vorzunehmen. Die App benötigt mehr Nutzerfeedback.

    Danke für die Stimme

  • Wie viel kostet Managing Rivaroxaban?

    Managing Rivaroxaban ist kostenlos.

  • Wie hoch ist der Umsatz von Managing Rivaroxaban?

    Um geschätzte Einnahmen der Managing Rivaroxaban-App und weitere AppStore-Einblicke zu erhalten, können Sie sich bei der AppTail Mobile Analytics Platform anmelden.

Benutzerbewertung
Die App ist in Pakistan noch nicht bewertet.
Bewertungsverlauf

Managing Rivaroxaban Bewertungen

Keine Bewertungen in Pakistan
Die App hat noch keine Bewertungen in Pakistan.

Store-Rankings

Ranking-Verlauf
App-Ranking-Verlauf noch nicht verfügbar
Kategorien-Rankings
Diagramm
Kategorie
Rang
Top Kostenlos
218

Managing Rivaroxaban Installationen

Letzte 30 Tage

Managing Rivaroxaban Umsatz

Letzte 30 Tage

Managing Rivaroxaban Einnahmen und Downloads

Gewinnen Sie wertvolle Einblicke in die Leistung von Managing Rivaroxaban mit unserer Analytik.
Melden Sie sich jetzt an, um Zugriff auf Downloads, Einnahmen und mehr zu erhalten.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.